OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Early investment in formulation strategies will maximize the chance of success.
Advances in simulation and the development of digital twins.
Different methods give different answers when calculating limits for impurities.
Automatic visual inspection machines and AI highlight inspection deficits.
Despite their promise, alternative drug delivery approaches are complex and must be justified.
Traditional statistical process control rules can be relaxed or adjusted to allow charting and evaluation of real-life data.
Novavax COVID-19 Vaccine Receives EUA in Indonesia
November 25, 2021
AstraZeneca has unveiled its new facility, The Discovery Centre, which will be used to support the company's focus on precision and specialized medicines, and to foster industry collaboration.
Eppendorf has donated €20,000 (US$22,400) to the European Molecular Biology Laboratory (EMBL) in support of the “Advancement of Women in Science” project.
The EC has granted marketing authorization for Gilead’s Trodelvy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer.
November 24, 2021
MilliporeSigma’s new ColorWheel flow cytometry portfolio is designed to create antibodies and dyes analogous to a primary conjugated antibody.
November 23, 2021
Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.
United States government contracts total approximately $1 billion to purchase sotrovimab, an investigational mAb.
November 22, 2021
Speed to market, flexibility, and digitalization are important topics in biopharmaceutical manufacturing.
November 19, 2021
Sartorius’ newly redesigned vacuum filtration units are designed to allow for faster and higher-capacity filtration while offering enhanced stability for sample processing.
FDA has amended its EUA for Pfizer-BioNTech’s and Moderna’s COVID-19 booster to include all individuals aged 18 or older.
Novo Nordisk’s 3.3 billion acquisition of Dicerna gives them access to their RNAi technology.